|
Dan Hartman joined deCODE in July 2005 and leads the company's drug development effort. Prior to joining deCODE he served for several years in senior clinical development positions at Pfizer including Global Clinical Leader Allergy and Respiratory Diseases; Clinical Exploratory Head Cardiovascular and Metabolic Diseases; and Experimental Medicine Therapy Area Leader Cardiovascular Metabolism and Anaderm. From 2000 to 2002 Dr. Hartman was Vice President of Worldwide Clinical Development at Esperion Therapeutics. Prior to joining Esperion he was Director Clinical Cardiovascular and Therapy Head thrombosis and Cardiopulmonary Disease at Pfizer. From 1995 to 1999 Dr. Hartman served in senior clinical research positions at Eli Lilly & Company. Dr. Hartman received his M.D. from Wayne State University held post-doctoral and faculty positions at the Indiana University School of Medicine. He is board certified in internal medicine and is a member of numerous medical societies. | 